Invitae

Last updated
Invitae Corporation
Company type Public
Expert Market :  NVTAQ
IndustryGenetic testing
Founded2010;14 years ago (2010)
Headquarters San Francisco, California, U.S.
Key people
Kenneth D. Knight (CEO) [1]
Revenue US$279.6 million (2020)
US$–608.9 million (2020)
Website www.invitae.com/en

Invitae Corp. is a biotechnology company that was created as a subsidiary of Genomic Health in 2010 and then spun-off in 2012. [2]

Contents

In 2017, Invitae acquired Good Start Genetics and CombiMatrix. [3] [4] In 2020, Invitae announced the acquisition of ArcherDX for $1.4 billion. [5] In 2021, Invitae announced the acquisition of health care AI startup Ciitizen for $325 million. [6]

In early 2024, Invitae filed for Chapter 11 bankruptcy protection, and later announced an agreement for an acquisition by Labcorp. [7]

CombiMatrix Corp.

CombiMatrix Corp. (Nasdaq :  CBMX) [8] was a clinical diagnostic laboratory specializing in pre-implantation genetic screening, miscarriage analysis, prenatal and pediatric diagnostics, offering DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies. As a full-scale cytogenetic and cytogenomic laboratory, CombiMatrix performs genetic testing utilizing a variety of advanced cytogenomic techniques, including chromosomal microarray analysis, standardized and customized fluorescence in situ hybridization (FISH) and high-resolution karyotyping. [9] CombiMatrix is dedicated to providing high-level clinical support for healthcare professionals in order to help them incorporate the results of complex genetic testing into patient-centered medical decision making.[ citation needed ]

In 2012 CombiMatrix shifted its focus from providing oncology genetic testing to developmental testing. Their focus is cytogenomic miscarriage analysis, prenatal analysis and postnatal/pediatric analysis. [10] [11]

History

In the mid-1990s, a PhD from Caltech invented a method of analyzing and immobilizing genetic material on the surface of a modified semiconductor wafer. The CombiMatrix microarray ("CombiMatrix" refers to combinatorial chemistry on a matrix array) was born and received US patents in the late '90s. Located in Mukilteo, Washington, the company received several rounds of private financings and filed to go public in November 2000. Unfortunately, CombiMatrix missed its "IPO window" by a few months due to the turmoil that was happening in the financial markets in late 2000 and early 2001, and then the events of Sept. 11 2001 put the final "nail in the coffin" to the company's fundraising plans at the time. So, CombiMatrix shifted gears and began pursuing several funded R&D projects to further develop its proprietary microarray technology with outside entities such as Roche Applied Sciences in Europe, biotech researchers in Japan as well as the U.S. Department of Defense. In late 2002, CombiMatrix merged with and became a wholly owned subsidiary of Acacia Research Corporation of Newport Beach, California. [12]

From 2002 to 2007, CombiMatrix continued its commercial development of "CustomArray" as it was called and began selling its DNA synthesis instruments and arrays to various R&D facilities throughout the United States, Europe and Asia. In an effort to diversify the company from the "tools" R&D sector, the company created CombiMatrix Molecular Diagnostics, Inc. and opened a diagnostics lab in Irvine, California, which was originally led by former US Labs employees with the intent of entering the much larger clinical diagnostics market using its proprietary microarray platform for oncology-related diagnostic services. CMD then branched into pediatric diagnostic testing by introducing other array technologies beyond the CustomArray platform. In 2007, CombiMatrix spun out from Acacia Research Corp. and became an independent public company in August of that year. [12]

By 2010, the clinical lab business was showing promise, while the legacy CustomArray tools business was not achieving the commercial success that was needed to grow the company. As a result, the CombiMatrix Board made the difficult decision to scuttle the CustomArray tools business in Washington state and instead focus all commercial and operational resources on the diagnostic services business in California. By the end of 2010, the Irvine CLIA lab was the sole remaining commercial operations of CombiMatrix.

Since that time, the company has launched several different genetic diagnostic tests in oncology, pediatric disorders and reproductive health, with the latter becoming the primary growth engine of the Company in recent years. As our Board has often said over the past three years in particular, we have become a "real, commercial company" at CombiMatrix. The company's recent success over the past 16 quarters of consistently increasing revenue and collections while decreasing costs and cash burn led to the successful sale of CombiMatrix to Invitae in November 2017.

On February 5, 2024, The Wall Street Journal reported that the company was preparing to file for bankruptcy. [13] The following day, the New York Stock Exchange announced it was delisting the company's stock and trading halted. [14] On February 13, 2024, Invitae declared Chapter 11 bankruptcy in New Jersey. [15]

CombiSNP Array

CombiMatrix uses the CombiSNP Array as their technology platform. SNP stands for Single nucleotide polymorphism probes. These probes allow for increased precision and greater diagnostic yield. This array contains more than 845,000 SNP markers covering both coding and non-coding human genome sequences. The median spatial resolution between probes is 1 Kb within gene rich regions and 5 Kb outside of gene-rich regions. [16]

Related Research Articles

<span class="mw-page-title-main">Agilent Technologies</span> American technology company

Agilent Technologies, Inc. is a global company headquartered in Santa Clara, California, that provides instruments, software, services, and consumables for laboratories. Agilent was established in 1999 as a spin-off from Hewlett-Packard. The resulting IPO of Agilent stock was the largest in the history of Silicon Valley at the time. From 1999 to 2014, the company produced optics, semiconductors, EDA software and test and measurement equipment for electronics; that division was spun off to form Keysight. Since then, the company has continued to expand into pharmaceutical, diagnostics & clinical, and academia & government (research) markets.

<span class="mw-page-title-main">Genetic testing</span> Medical test

Genetic testing, also known as DNA testing, is used to identify changes in DNA sequence or chromosome structure. Genetic testing can also include measuring the results of genetic changes, such as RNA analysis as an output of gene expression, or through biochemical analysis to measure specific protein output. In a medical setting, genetic testing can be used to diagnose or rule out suspected genetic disorders, predict risks for specific conditions, or gain information that can be used to customize medical treatments based on an individual's genetic makeup. Genetic testing can also be used to determine biological relatives, such as a child's biological parentage through DNA paternity testing, or be used to broadly predict an individual's ancestry. Genetic testing of plants and animals can be used for similar reasons as in humans, to gain information used for selective breeding, or for efforts to boost genetic diversity in endangered populations.

Affymetrix is now Applied Biosystems, a brand of DNA microarray products sold by Thermo Fisher Scientific that originated with an American biotechnology research and development and manufacturing company of the same name. The Santa Clara, California-based Affymetrix, Inc. now a part of Thermo Fisher Scientific was co-founded by Alex Zaffaroni and Stephen Fodor. Stephen Fodor and his group, based on their earlier development of methods to fabricate DNA microarrays using semiconductor manufacturing techniques.

<span class="mw-page-title-main">Labcorp Drug Development</span> Contract research organization

Labcorp Drug Development is a contract research organization headquartered in Burlington, North Carolina, providing nonclinical, preclinical, clinical and commercialization services to pharmaceutical and biotechnology industries. Formerly called Covance, the company is part of Labcorp, which employs more than 70,000 people worldwide.

Comparative genomic hybridization (CGH) is a molecular cytogenetic method for analysing copy number variations (CNVs) relative to ploidy level in the DNA of a test sample compared to a reference sample, without the need for culturing cells. The aim of this technique is to quickly and efficiently compare two genomic DNA samples arising from two sources, which are most often closely related, because it is suspected that they contain differences in terms of either gains or losses of either whole chromosomes or subchromosomal regions. This technique was originally developed for the evaluation of the differences between the chromosomal complements of solid tumor and normal tissue, and has an improved resolution of 5–10 megabases compared to the more traditional cytogenetic analysis techniques of giemsa banding and fluorescence in situ hybridization (FISH) which are limited by the resolution of the microscope utilized.

<span class="mw-page-title-main">Acacia Research</span>

Acacia Research Corporation is a publicly traded American company based in New York City. Acacia partners with patent owners such as inventors and universities to license patents that are infringed. Roughly 95% of the company's business involves licensing infringed patents on behalf of patent owners to corporations through patent litigation.

Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.

<span class="mw-page-title-main">Tissue microarray</span>

Tissue microarrays consist of paraffin blocks in which up to 1000 separate tissue cores are assembled in array fashion to allow multiplex histological analysis.

<span class="mw-page-title-main">Genzyme</span> Company

Genzyme was an American biotechnology company based in Cambridge, Massachusetts. Since its acquisition in 2011, Genzyme has been a fully owned subsidiary of Sanofi. In 2010, Genzyme was the world's third-largest biotechnology company, employing more than 11,000 people around the world. As a subsidiary of Sanofi, Genzyme has a presence in approximately 65 countries, including 17 manufacturing facilities and 9 genetic-testing laboratories. Its products are also sold in 90 countries. In 2007, Genzyme generated $3.8 billion in revenue with more than 25 products on the market. In 2006 and 2007, Genzyme was named one of Fortune magazine’s “100 Best Companies to Work for”. The company donated $83 million worth of products worldwide; in 2006, it made $11 million in cash donations. In 2005, Genzyme was awarded the National Medal of Technology, the highest level of honor awarded by the president of the United States to America's leading innovators. In February 2022, Sanofi's new corporate brand was unveiled and former entity "Sanofi Genzyme" got integrated into Sanofi.

In molecular biology, SNP array is a type of DNA microarray which is used to detect polymorphisms within a population. A single nucleotide polymorphism (SNP), a variation at a single site in DNA, is the most frequent type of variation in the genome. Around 335 million SNPs have been identified in the human genome, 15 million of which are present at frequencies of 1% or higher across different populations worldwide.

<span class="mw-page-title-main">Medical laboratory</span> Principles of management with special reference to medical science

A medical laboratory or clinical laboratory is a laboratory where tests are conducted out on clinical specimens to obtain information about the health of a patient to aid in diagnosis, treatment, and prevention of disease. Clinical medical laboratories are an example of applied science, as opposed to research laboratories that focus on basic science, such as found in some academic institutions.

Laboratory Corporation of America Holdings, more commonly known as Labcorp, is an American healthcare company headquartered in Burlington, North Carolina. It operates one of the largest clinical laboratory networks in the world, with a United States network of 36 primary laboratories. Before a merger with National Health Laboratory in 1995, the company operated under the name Roche BioMedical. Labcorp performs its largest volume of specialty testing at its Center for Esoteric Testing in Burlington, North Carolina, where the company is headquartered. As of 2018, Labcorp processes 2.5 million lab tests weekly.

Rosetta Genomics Ltd. was a molecular diagnostics company with offices in Israel and the United States that uses micro-ribonucleic acid (microRNA) biomarkers to develop diagnostic tests designed to differentiate between various types of cancer. The company expects the first three tests based on its technology to be submitted for regulatory approval in 2008. The diagnostic tests will differentiate between squamous and non-squamous non-small cell lung cancer (NSCLC); differentiate between adenocarcinoma and peritoneal mesothelioma; and seek to identify the origin of tumors in patients representing cancer of unknown primary (CUP). Using a single microRNA, the highly sensitive, highly specific test for squamous and non-squamous lung cancer has passed the prevalidation phase and has been submitted for approval to the New York State Department of Health Clinical Laboratory Evaluation Program in April 2008.

Sequenom, Inc. is an American company based in San Diego, California. It develops enabling molecular technologies, and highly sensitive laboratory genetic tests for NIPT. Sequenom's wholly owned subsidiary, Sequenom Center for Molecular Medicine (SCMM), offers multiple clinical molecular genetics tests to patients, including MaterniT21, plus a noninvasive prenatal test for trisomy 21, trisomy 18, and trisomy 13, and the SensiGene RHD Fetal RHD genotyping test.

<span class="mw-page-title-main">MAGIChip</span>

MAGIChips, also known as "microarrays of gel-immobilized compounds on a chip" or "three-dimensional DNA microarrays", are devices for molecular hybridization produced by immobilizing oligonucleotides, DNA, enzymes, antibodies, and other compounds on a photopolymerized micromatrix of polyacrylamide gel pads of 100x100x20 μm or smaller size. This technology is used for analysis of nucleic acid hybridization, specific binding of DNA, and low-molecular weight compounds with proteins, and protein-protein interactions.

Virtual karyotype is the digital information reflecting a karyotype, resulting from the analysis of short sequences of DNA from specific loci all over the genome, which are isolated and enumerated. It detects genomic copy number variations at a higher resolution for level than conventional karyotyping or chromosome-based comparative genomic hybridization (CGH). The main methods used for creating virtual karyotypes are array-comparative genomic hybridization and SNP arrays.

FlexGen was a biotechnology company based in Leiden, Netherlands. FlexGen was a spin-off from Leiden University Medical Centre and Dutch Space and had proprietary technologies for laser based in-situ synthesis of oligonucleotides and other biomolecules. On 21 December 2015, Flexgen Bv in Leiden was declared bankrupt by the court in Gelderland Source.

<span class="mw-page-title-main">Molecular diagnostics</span> Collection of techniques used to analyze biological markers in the genome and proteome

Molecular diagnostics is a collection of techniques used to analyze biological markers in the genome and proteome, and how their cells express their genes as proteins, applying molecular biology to medical testing. In medicine the technique is used to diagnose and monitor disease, detect risk, and decide which therapies will work best for individual patients, and in agricultural biosecurity similarly to monitor crop- and livestock disease, estimate risk, and decide what quarantine measures must be taken.

OPKO Health is a medical test and medication company focused on diagnostics and pharmaceuticals. The company is a publicly traded company on NASDAQ and TASE under the symbol "OPK".

Elective genetic and genomic testing are DNA tests performed for an individual who does not have an indication for testing. An elective genetic test analyzes selected sites in the human genome while an elective genomic test analyzes the entire human genome. Some elective genetic and genomic tests require a physician to order the test to ensure that individuals understand the risks and benefits of testing as well as the results. Other DNA-based tests, such as a genealogical DNA test do not require a physician's order. Elective testing is generally not paid for by health insurance companies. With the advent of personalized medicine, also called precision medicine, an increasing number of individuals are undertaking elective genetic and genomic testing.

References

  1. ↑ "Invitae Announces Leadership Transition". 18 July 2022.
  2. ↑ Lash, Alex (20 October 2015). "What's Your DNA Worth? The Scramble To Cash In On the Genome". exome. Archived from the original on 2015-10-21. Retrieved 10 January 2017.
  3. ↑ "Invitae Acquiring Good Start Genetics and CombiMatrix, Adding Comprehensive Reproductive Health Capabilities to Serve Every Stage of Life". Invitae. 2017-08-03. Archived from the original on 2021-01-30. Retrieved 2021-01-30.
  4. ↑ Pedersen, Amanda (2017-08-01). "Invitae is Going After Prenatal Screening in a Big Way". MDDIonline.com. Archived from the original on 2021-01-30.
  5. ↑ Gatlin, Allison (2020-06-22). "Genetic Testing Behemoth Invitae Rockets 45% On $1.4 Billion Acquisition". investors.com. Archived from the original on 2020-06-23. Retrieved 2021-01-30.
  6. ↑ "Invitae to Acquire Ciitizen to Strengthen its Patient-Consented Health Data Platform to Improve Personal Outcomes and Global Research". ir.invitae.com. Retrieved 2021-10-07.
  7. ↑ "Invitae Enters into Agreement with Labcorp for Sale of Business". Invitae. 24 April 2024.
  8. ↑ "Sector Update: Health Care Stocks Ending in Deep Hole; CombiMatrix Climbs Off All-Time Lows After Reporting Big Growth in Testing Volumes". nasdaq.com. Retrieved 13 October 2014.
  9. ↑ "CombiMatrix (CBMX) Sees Record Prenatal Testing Volumes in Q314". streetinsider.com. Retrieved 13 October 2014.
  10. ↑ "CombiMatrix Corporation". The New York Times . Retrieved 30 October 2014.
  11. ↑ "Chromosomal Microarrays for Prenatal Testing: Interview with CombiMatrix CEO Mark McDonough". medgadget.com. 18 August 2014. Retrieved 30 October 2014.
  12. 1 2 "Form 10-K (2008)". SEC.gov. Retrieved 2020-01-30.
  13. ↑ "SoftBank-Backed Medical Genetics Company Invitae Prepares for Bankruptcy". The Wall Street Journal. 2024-02-05.
  14. ↑ Pan, Eddie (2024-02-06). "The New York Stock Exchange Will Start Delisting Invitae (NVTA) Stock". InvestorPlace. Retrieved 2024-02-06.
  15. ↑ "SoftBank backed genetic test firm Invitae files for Chapter 11". Bloomberg Law. February 13, 2024. Retrieved February 14, 2024.
  16. ↑ "CombiMatrix Corp 's Pediatric development disorders analysis test granted conditional approval from New York State Department of Health". reuters.com. Retrieved 30 October 2014.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.